Mesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast Limited reported substantial revenue growth to US$120 million for the fiscal year ended June 30, 2026, driven primarily by successful US commercial launch of RYONCIL for pediatric steroid-refractory acute graft versus host disease (SR-aGvHD). The company highlighted operational achievements including label expansion efforts for adults wit…